Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is described in its public communications as a company that owns rights to pharmaceutical royalties and operates as a pharmaceutical royalty company. Its recurring news releases focus on financial results and business updates related to this royalty-based model. Each quarter, the company issues press releases detailing net income or net loss from continuing operations, license revenues primarily associated with the Mayne License Agreement, and total operating expenses from continuing operations.
These earnings announcements highlight how changes in sales of licensed products by TherapeuticsMD’s licensees affect license revenue, and how the company’s transition from a commercializing pharmaceutical business to a royalty-based business has influenced its cost structure. The company frequently discusses reductions in operating expenses, including lower general and administrative costs, and refers to efficiencies realized as a royalty-based business with more limited infrastructure.
Another recurring theme in TherapeuticsMD’s news is its evaluation of strategic alternatives. In multiple press releases, the company states that it is exploring a variety of potential transactions, which may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the company. It also notes that there can be no assurance of any particular outcome and that no timetable has been set for this process.
Visitors to the TXMD news page can review this sequence of financial updates, commentary on the company’s royalty assets, and disclosures about its strategic review process. For investors and followers of TXMD stock, these news items provide insight into the company’s royalty revenue trends, expense profile, and the status of its exploration of possible strategic alternatives over time.
TherapeuticsMD, Inc. (NASDAQ: TXMD) and Theramex announced the approval of BIJUVE® in the UK and BIJUVA® in Belgium by respective regulatory agencies. This approval follows a decentralized procedure completed in February for several EU countries. Both medications represent the first oral combined hormone replacement therapy utilizing bio-identical hormones for post-menopausal women. Theramex will pay milestone and royalty fees to TherapeuticsMD based on sales and approvals in Europe.
TherapeuticsMD reported record net product revenue for Q4 2020 and the full year, driven by strong sales of its products. Total revenue for Q4 was $22.6 million, a rise from $15.9 million in Q4 2019. The company recorded a net loss of $42.1 million for Q4, an improvement from $49.4 million a year earlier. Operating expenses increased to $51.6 million in Q4, mainly attributed to ongoing product launches and brand management. The cash on hand at year-end was $80.5 million. The company is adjusting its revenue covenants and plans further debt repayments in 2021.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will participate in two upcoming investor conferences, showcasing its commitment to women’s healthcare. The first event is the Cowen Virtual Healthcare Conference on March 3, 2021, at 3:20 p.m. Eastern time. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, with a presentation available at 11:00 a.m. Eastern time. Live webcasts can be accessed through the company’s website. TherapeuticsMD focuses on innovative products for women, addressing key health issues throughout their lives.
TherapeuticsMD, Inc. (NASDAQ: TXMD) has announced its fourth quarter 2020 financial results reporting on Tuesday, March 2, 2021, before U.S. market opening. The company will hold a conference call at 8:30 a.m. ET to discuss the results and provide a business update. Interested parties can access the call via telephone at 866-665-9531 for U.S. callers or 724-987-6977 for international calls, using access code 6184646. The event will also be available via a live audio webcast on their website.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed its underwritten public offering of 59,459,460 shares of common stock, generating approximately $97.1 million in net proceeds. The offering was fully sold by TherapeuticsMD, which has also granted the underwriter a 30-day option to acquire up to 8.9 million additional shares. Cantor Fitzgerald & Co. served as the sole bookrunning manager. This follows a previously effective shelf registration statement filed with the SEC.
TherapeuticsMD, Inc. (NASDAQ:TXMD) announced an underwritten public offering of approximately 59.5 million shares at a gross proceeds of $110 million, closing expected around February 16, 2021. Cantor Fitzgerald & Co. is the bookrunning manager, with a 30-day option for the underwriter to purchase an additional 8.9 million shares. Proceeds will be used for commercialization of FDA-approved products like IMVEXXY®, BIJUVA®, and ANNOVERA®, along with debt discharge and working capital.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has announced an underwritten public offering of its common stock, allowing the underwriter a 30-day option to purchase an additional 15% of offered shares. All shares will be sold by the company, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. Proceeds from the offering are intended for commercialization of three FDA-approved products: IMVEXXY®, BIJUVA®, and ANNOVERA®, as well as to reduce existing debt and general corporate purposes.
TherapeuticsMD, Inc. (NASDAQ: TXMD) will participate in two upcoming investor conferences: the H.C. Wainwright BioConnect Conference from January 11-14, 2021, and the J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 8:20 a.m. Eastern time. Presentations will be available online during the events. TherapeuticsMD specializes in women’s healthcare, focusing on products for family planning, reproductive health, and menopause management. For more details, visit therapeuticsmd.com.
TherapeuticsMD (NASDAQ:TXMD) has launched Just Say Vagina, a campaign aimed at empowering women to openly discuss reproductive health issues. Comedian Whitney Cummings, who has utilized the ANNOVERA® contraceptive, will be featured, encouraging women to abandon euphemisms in favor of direct communication about their needs. The press release highlights that 45% of unintended pregnancies in the U.S. stem from inconsistent contraceptive use, and 47% of women discontinue birth control due to dissatisfaction.
TherapeuticsMD, Inc. (NASDAQ:TXMD) has successfully closed an underwritten public offering of 23,437,500 shares of its common stock, generating net proceeds of approximately $27.5 million after deducting underwriting discounts and commissions. All shares were sold by TherapeuticsMD, with Cantor Fitzgerald & Co. serving as the sole bookrunning manager. The offering was conducted under a previously declared effective shelf registration statement with the SEC.